RUO gantenerumab是由Hoffmann-La Roche制药公司开发的用于治疗阿尔茨海默病的单克隆抗体。Gantenerumab结合并清除聚集的β淀粉样蛋白纤维。由于缺乏疗效,gantenerumab的III期临床试验提前停止。 Gantenerumab生物仿制药-研究级该产品同种型对照:Bulk Human IgG1 Isotype Control (IB1) [ICH2254] 缓冲液:ICH3002 浓度:5mg/ml 纯度:>95% by SDS-PAGE 内毒素:≤ 1.0 EU/mg as determined by the LAL method 制剂:Sterile, preservative-free, solution in PBS. BSA and Azide free.